Related Experiment Video

Updated: Oct 12, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.4K

[Homologous recombination deficiency and PARP inhibitors in therapeutics]

Hélène Salaün1, Mathilde Saint-Ghislain2, Audrey Bellesoeur3

  • 1PSL research university, institut Curie, medical oncology department, 35, rue Dailly, 92210 Saint-Cloud, France.

Bulletin Du Cancer
|November 20, 2021
PubMed

Insights

PARP inhibitors show efficacy in various cancers, including ovarian and breast cancer. Research is exploring their use with other therapies and overcoming resistance mechanisms for broader patient access.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Poly (ADP-ribose) polymerase (PARP) inhibitors are effective treatments for several cancer types.
  • Their prescription is currently limited to patients with specific genetic alterations like BRCA mutations or homologous recombination deficiency (HRD).

Purpose of the Study:

  • To review the current landscape and future directions of PARP inhibitor therapy.
  • To highlight diagnostic advancements and emerging therapeutic combinations.

Main Methods:

  • Literature review of ongoing and completed clinical trials.
  • Analysis of diagnostic methods for homologous recombination deficiency (HRD).

Main Results:

  • PARP inhibitors are approved for BRCA-mutated or HRD-positive ovarian, breast, prostate, and pancreatic cancers.
  • The myChoice CDx test aids in diagnosing HRD for PARP inhibitor eligibility.
  • Investigational studies are exploring combinations with chemotherapy, targeted therapies, radiotherapy, and immune checkpoint inhibitors.

Conclusions:

  • PARP inhibitors represent a significant advancement in cancer treatment, particularly for HRD-positive tumors.
  • Ongoing research aims to expand their application and overcome resistance mechanisms, improving patient outcomes.
Keywords:
Déficit de la recombinaison homologueGenomic signaturesHomologous recombination deficiencyInhibiteurs de PARPPARP inhibitorSignatures génomiques

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.2K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.9K

Related Concept Videos

Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
55.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.0K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
6.2K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.3K
Crossing Over01:30

Crossing Over

Crossing over is the exchange of genetic information between homologous chromosomes during prophase I of meiosis I. Genetic recombination gives rise to allelic diversity in the newly formed daughter cells. In humans, crossing over produces genetically distinct haploid egg and sperm cells that undergo fertilization to produce unique offspring. Before cell division starts, the germ cell’s chromosome(s) undergo duplication in the S phase of the cell cycle. As the cells enter prophase I,...
4.9K